Clinical Trial Update: Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating rapamycin added to high-dose etoposide and cytarabine in relapsed/refractory aggressive lymphoid malignancies; the study was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Burkitt Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Etoposide (Etoposide)
• Rapamycin (sirolimus)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: ALL, Burkitt's Lymphoma | Phase 1, Phase 2 | Status: TERMINATED